Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.

Human pathology - 1 Apr 2002

Maeda Kyoko, Tsuda Hiroshi, Hashiguchi Yasunori, Yamamoto Kumio, Inoue Takeshi, Ishiko Osamu, Ogita Sachio

Abstract excerpt

We analyzed the mechanism of estrogen receptor (ER) loss and status of the p53 pathway in 64 cases of endometrial cancer. 26.6% (17 of 64) of endometrial cancers lost ER. Methylation of the ER CpG island was significantly related to ER status (P = 0.0074). However, the methylation site of the ER CpG island differed between breast and endometrial cancers. The abnormal expression rate of p14ARF, MDM2, p53, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Endometrioid
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Polymorphism, Single-Stranded Conformational

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-mdm2

Share to Receptors, Estrogen

Share to Tumor Suppressor Protein p14ARF

Source

Identifiers

PMID: 12055672
DOI: 10.1053/hupa.2002.124720

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.PMID 12055672Read ↗

Clinical Profile and Survival Outcome of Endometrial Cancer with p53 MutationSemantic proximity Read ↗

p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.Semantic proximity Read ↗

p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?Semantic proximity Read ↗

Distinctive p53 and mdm2 Immunohistochemical Expression Profiles Suggest Different Pathogenetic Pathways in Poorly Differentiated Endometrial CarcinomaSemantic proximity Read ↗

Clinical implication of estrogen-related receptor (ERR) expression in uterine endometrial cancersSemantic proximity Read ↗

p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status.Semantic proximity Read ↗

Molecular basis of endometrial cancerSemantic proximity Read ↗

Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.Semantic proximity Read ↗

The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways.Semantic proximity Read ↗

Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma.Semantic proximity Read ↗

Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.Semantic proximity Read ↗

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.